Atossa Therapeutics
| Public | |
| Traded as | NASDAQ: ATOS |
| ISIN | 🆔 |
| Industry | Biotechnology |
| Founded 📆 | 2009 |
| Founder 👔 | Dr. Steven Quay |
| Headquarters 🏙️ | Seattle, Washington |
Area served 🗺️ | |
Key people | Dr. Steven Quay (CEO) |
| Products 📟 | Breast Cancer Pharmaceuticals
The COVID-19 HOPE Program COVID-19 Nasal Spray |
| Members | |
Number of employees | |
| 🌐 Website | www |
| 📇 Address | |
| 📞 telephone | |
Atossa Therapeutics NASDAQ: ATOS is a Seattle-based clinical-stage biopharmaceutical company[1] known for it's groundbreaking work on breast cancer and COVID-19 illnesses.[2] They are became notable in 2020 when the FDA issued a “Safe to Proceed” letter permitting the use of Atossa’s oral Endoxifen.[3][4] The company is also developing AT-301 for COVID-19 affected patients for treatment at home.[5]
The company went public and became listed[6] on NASDAQ stock exchange under the symbol ATOS in 2012.[7]
History[edit]
Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on medicines. Atossa’s current focus is on breast cancer and COVID-19. Thier innovative therapies and delivery methods benefit COVID-19 patients and transform breast cancer treatment.[8]
References[edit]
- ↑ Inc, Atossa Therapeutics (2021-05-14). "Atossa Therapeutics Announces First Quarter 2021 Financial Results and Provides Corporate Update". GlobeNewswire News Room. Retrieved 2021-05-20.
- ↑ "Atossa Comapny Information". NASDAQ. Unknown parameter
|url-status=ignored (help) - ↑ "Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA's Expanded Access Pathway". finance.yahoo.com. Retrieved 2021-04-30.
- ↑ "Atossa Therapeutics Inc (ATOS) Stock Moves up Again: Up 55% in a Week – Own Snap". Retrieved 2021-04-30.
- ↑ Hudson, Kate (2021-04-12). "Atossa Therapeutics Inc (NASDAQ:ATOS) Reports Positive Interim Results From Phase 2 Clinical Trial Of Endoxifen In Q4 2020: FDA Permits Expanded Access Of Endoxifen To Treat Ovarian Cancer Patients". BioPharmaJournal. Retrieved 2021-04-30.
- ↑ "Atossa Therapeutics (ATOS) Stock: Over 17% Increase Explanation". Pulse 2.0. 2021-05-14. Retrieved 2021-05-20.
- ↑ "ATOS Stock Forecast, Price & News (Atossa Therapeutics)". www.marketbeat.com. Retrieved 2021-04-30.
- ↑ Inc, Else Nutrition Holdings. "Could This Company be the "Future Oatly" of the $109.1 Billion Infant Formula Market?". MicroSmallCap. Retrieved 2021-07-14.
External links[edit]
This article "Atossa Therapeutics" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Atossa Therapeutics. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
